Unjha Formulations

Unjha Formulations Gross Margin

The Gross Margin of Unjha Formulations (531762.BO) as of Oct 27, 2026 is 21.31 %. In the previous year, Gross Margin was 17.60 % — a change of 21.07% (higher).

Gross Margin

21.31 %

YoY

21.07%

Last updated:

Gross Margin of Unjha Formulations is 2026 21.31 % . Gross Margin of Unjha Formulations was 2025 17.60 % . It decreases by 21.07% higher compared to the previous year.

For Unjha Formulations, the gross margin of 21.3% is up versus 19.1% a few years ago.

The Unjha Formulations Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2019
23.34 INR
Jan 1, 2020
22.64 INR
Jan 1, 2021
23.36 INR
Jan 1, 2022
19.13 INR
Jan 1, 2023
20.24 INR
Jan 1, 2024
15.92 INR
Jan 1, 2025
17.60 INR
Jan 1, 2026
21.31 INR
The Unjha Formulations Gross Margin history
YEARGross MarginYoY
21.31 %+21.07%
17.60 %+10.55%
15.92 %-21.33%
20.24 %+5.84%
19.13 %-18.13%
23.36 %+3.19%
22.64 %-3.02%
23.34 %+42.76%
16.35 %+46.68%
11.15 %-24.88%
14.84 %-7.17%
15.99 %-21.73%
20.42 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Unjha Formulations Stock analysis

What does Unjha Formulations do? Unjha Formulations Ltd. generates revenue through the manufacturing and export of Ayurvedic products, primarily targeting international markets. The company's key products include Fibron SF Powder, Albendazole Bolus, and Fibermate, which are isabgol-based formulations. Anchor Sat-Isabgol, available in 50g, 100g, 200g, and 400g sizes, is a flagship product, while Fibron and Fibron SF (Sugar Free) come in 100g and 300g packages. The firm focuses on export markets for its veterinary medicinal formulations not for human use, alongside its Ayurvedic powder and tablet lines. The company's revenue streams are derived from the sale of Fibron SF Powder, Albendazole Bolus, and Fibermate to international buyers seeking Ayurvedic and veterinary products. Anchor Sat-Isabgol is sold in multiple sizes, catering to consumer demand for isabgol-based health supplements. Unjha Formulations Ltd. also produces Small Volume Ayurvedic Isabgol powder, which is exported globally. The primary customers are international importers and distributors specializing in Ayurvedic and veterinary medicinal products. Export markets drive the company's business model, with Fibron SF Powder and Fibron being key revenue contributors. The firm's veterinary medicinal formulation not for human use, including Albendazole Bolus, targets agricultural and livestock sectors. Anchor Sat-Isabgol's availability in various sizes ensures broad market reach, while the company's focus on isabgol-based formulations aligns with global demand for natural health products. Unjha Formulations is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Unjha Formulations stock

Gross Margin of Unjha Formulations is 21.31 % in 2026.

Gross Margin of Unjha Formulations changed from 17.60 % to 21.31 %, representing a 21.07% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin Unjha Formulations since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's Unjha Formulations with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Unjha Formulations

All Key Metrics — Unjha Formulations